Replies to post #243661 on Biotech Values

[dewophile]

While the strong dollar is going to make US based bios a bit costlier for ex-US companies, the fact they derive a disproportionate amount of revenue in dollars helps boost earnings so the current currency environment is good for a company like NVO

[maumar]

It's trading at $20.07 right now so I guess some investors are hoping for a higher bid.

[DewDiligence]

Addendum—NVO was almost certainly one of the two companies PFE is known to have outbid in the acquisition of GBT (#msg-169612752). JNJ was the other one.